These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 26048902)
21. Bayesian two-stage designs for phase II clinical trials. Tan SB; Machin D Stat Med; 2006 Oct; 25(19):3407-8. PubMed ID: 16847890 [No Abstract] [Full Text] [Related]
22. Bayesian interim analysis of phase II cancer clinical trials. Heitjan DF Stat Med; 1997 Aug; 16(16):1791-802. PubMed ID: 9280033 [TBL] [Abstract][Full Text] [Related]
23. [Phases 0, 1 and 2 oncology clinical trials: current questions]. Penel N; Fournier C; Stéphanie C Bull Cancer; 2010 Jan; 97(1):55-63. PubMed ID: 20080458 [TBL] [Abstract][Full Text] [Related]
24. Adaptive group sequential design for phase II clinical trials: a Bayesian decision theoretic approach. Chen Y; Smith BJ Stat Med; 2009 Nov; 28(27):3347-62. PubMed ID: 19725024 [TBL] [Abstract][Full Text] [Related]
25. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials. Zhao L; Woodworth G Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology. Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349 [TBL] [Abstract][Full Text] [Related]
27. Use of predictive probabilities in phase II and phase III clinical trials. Johns D; Andersen JS J Biopharm Stat; 1999 Mar; 9(1):67-79. PubMed ID: 10091910 [TBL] [Abstract][Full Text] [Related]
28. One-sided sequential stopping boundaries for clinical trials: a decision-theoretic approach. Berry DA; Ho CH Biometrics; 1988 Mar; 44(1):219-27. PubMed ID: 3358990 [TBL] [Abstract][Full Text] [Related]
30. Bayesian adaptive decision-theoretic designs for multi-arm multi-stage clinical trials. Bassi A; Berkhof J; de Jong D; van de Ven PM Stat Methods Med Res; 2021 Mar; 30(3):717-730. PubMed ID: 33243087 [TBL] [Abstract][Full Text] [Related]
31. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials. Xie F; Ji Y; Tremmel L Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247 [TBL] [Abstract][Full Text] [Related]
32. Bayesian design of single-arm phase II clinical trials with continuous monitoring. Johnson VE; Cook JD Clin Trials; 2009 Jun; 6(3):217-26. PubMed ID: 19528131 [TBL] [Abstract][Full Text] [Related]
33. A Bayesian predictive strategy for an adaptive two-stage design in phase II clinical trials. Sambucini V Stat Med; 2010 Jun; 29(13):1430-42. PubMed ID: 20099246 [TBL] [Abstract][Full Text] [Related]
34. Bayesian designs and the control of frequentist characteristics: a practical solution. Ventz S; Trippa L Biometrics; 2015 Mar; 71(1):218-226. PubMed ID: 25196832 [TBL] [Abstract][Full Text] [Related]
35. Adaptive design of confirmatory trials: Advances and challenges. Lai TL; Lavori PW; Tsang KW Contemp Clin Trials; 2015 Nov; 45(Pt A):93-102. PubMed ID: 26079372 [TBL] [Abstract][Full Text] [Related]
36. Optimal and minimax three-stage designs for phase II oncology clinical trials. Chen K; Shan M Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337 [TBL] [Abstract][Full Text] [Related]
37. Accounting for uncertainty in the historical response rate of the standard treatment in single-arm two-stage designs based on Bayesian power functions. Matano F; Sambucini V Pharm Stat; 2016 Nov; 15(6):517-530. PubMed ID: 27766770 [TBL] [Abstract][Full Text] [Related]
39. A decision-theoretic evaluation of early stopping rules. Heitjan DF; Houts PS; Harvey HA Stat Med; 1992 Mar; 11(5):673-83. PubMed ID: 1594809 [TBL] [Abstract][Full Text] [Related]
40. A randomized two-stage design for phase II clinical trials based on a Bayesian predictive approach. Cellamare M; Sambucini V Stat Med; 2015 Mar; 34(6):1059-78. PubMed ID: 25545805 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]